Allogene Therapeutics, Inc. (ALLO)

Profile

https://allogene.com

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, or donor-derived, CAR T cell therapies for cancer and autoimmune disease. The company’s current work centers on investigational off-the-shelf cell therapy candidates designed to be manufactured from healthy donor cells and delivered more readily to patients than individualized treatments. Its pipeline includes programs targeting blood cancers, solid tumors, and autoimmune disorders, with emphasis on areas such as large B-cell lymphoma, renal cell carcinoma, and other oncology indications. Allogene Therapeutics also develops supporting technologies and manufacturing capabilities that are intended to improve the consistency, scalability, and accessibility of its cell therapy platform. Headquartered in South San Francisco, California, Allogene Therapeutics plays a specialized role in the immuno-oncology market as a developer of next-generation cell therapies for complex diseases.